BEAM
HEALTHCAREBeam Therapeutics Inc
AI Insight
What's Moving BEAM Today?
No stock-specific AI insight has been generated for BEAM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$15.60$36.88
$33.20
Fundamentals
Market Cap$3.7B
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-5.8%
Profit Margin-40.2%
Debt / Equity—
Trading
Volume3.6M
Avg Volume (10D)—
Shares Outstanding102.9M
BEAM News
25 articles- BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for PhenylketonuriaYahoo Finance·Jun 19, 2026
- Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug AdministrationYahoo Finance·Jun 18, 2026
- Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?Yahoo Finance·Jun 16, 2026
- Beam Therapeutics Stock Soars 21% in Three Months: Here's WhyYahoo Finance·Jun 16, 2026
- 3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026Yahoo Finance·Jun 2, 2026
- Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATDYahoo Finance·May 28, 2026
- Beam Therapeutics Accelerated Approval Bid Puts BEAM-302 At Center StageSimply Wall Street·May 26, 2026
- Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?The Motley Fool·May 26, 2026
- Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program AdvancesMarketbeat·May 20, 2026
- Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) StockYahoo Finance·May 20, 2026
- Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?Yahoo Finance·May 19, 2026
- Beam Therapeutics Data Puts BEAM 302 And AAT Disease In FocusYahoo Finance·May 19, 2026
- Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International ConferenceYahoo Finance·May 18, 2026
- Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?Motley Fool·May 18, 2026
- Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1Yahoo Finance·May 13, 2026
- Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare ConferenceYahoo Finance·May 13, 2026
- Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026Yahoo Finance·May 12, 2026
- Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their EstimatesYahoo Finance·May 11, 2026
- Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?Simply Wall Street·May 10, 2026
- BEAM's Q1 Loss Wider Than Expected, Revenues Beat EstimatesYahoo Finance·May 8, 2026
- Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesYahoo Finance·May 7, 2026
- Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.The Motley Fool·Apr 11, 2026
- Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical ApplicationsGlobeNewswire Inc.·Apr 7, 2026
- Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentGlobeNewswire Inc.·Mar 25, 2026
All 25 articles loaded
Price Data
Open$35.26
Previous Close$35.53
Day High$36.67
Day Low$32.79
52 Week High$36.88
52 Week Low$15.60
52-Week Range
$15.60$36.88
$33.20
Fundamentals
Market Cap$3.7B
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-5.8%
Profit Margin-40.2%
Debt / Equity—
Trading
Volume3.6M
Avg Volume (10D)—
Shares Outstanding102.9M
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—